Optimal timing for activation of sigma 1 receptor in the Pde6b
Animals
Cyclic Nucleotide Phosphodiesterases, Type 6
/ metabolism
Disease Models, Animal
Electroretinography
Mice
Mice, Inbred C57BL
Receptors, sigma
/ metabolism
Retinal Cone Photoreceptor Cells
/ metabolism
Retinal Rod Photoreceptor Cells
/ metabolism
Retinitis Pigmentosa
/ metabolism
Tomography, Optical Coherence
Sigma-1 Receptor
ERG
OCT
Pentazocine
Retinal degeneration
Retinitis pigmentosa
Sigma 1 receptor
optomotry
rd10 mouse
Journal
Experimental eye research
ISSN: 1096-0007
Titre abrégé: Exp Eye Res
Pays: England
ID NLM: 0370707
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
09
10
2020
revised:
24
11
2020
accepted:
07
12
2020
pubmed:
15
12
2020
medline:
27
4
2021
entrez:
14
12
2020
Statut:
ppublish
Résumé
Sigma 1 Receptor (Sig1R), a pluripotent modulator of cell survival, is a promising target for treatment of retinal degenerative diseases. Previously, we reported that administration of the high-affinity, high-specificity Sig1R ligand (+)-pentazocine, ((+)-PTZ) beginning at post-natal day 14 (P14) and continuing every other day improves visual acuity and delays loss of photoreceptor cells (PRCs) in the Pde6βrd10/J (rd10) mouse model of retinitis pigmentosa. Whether administration of (+)-PTZ, at time points concomitant with (P18) or following (P21, P24) onset of PRC death, would prove neuroprotective was investigated in this study. Rd10 mice were administered (+)-PTZ intraperitoneally [0.5 mg/kg], starting at either P14, P18, P21 or P24. Injections continued every other day through P42. Visual acuity was assessed using the optokinetic tracking response (OKR). Rd10 mice treated with (+)-PTZ beginning at P14 retained visual acuity for the duration of the study (~0.33 c/d at P21, ~0.38 c/d at P28, ~0.32 c/d at P35, ~0.32 c/d at P42), whereas mice injected beginning at P18, P21, P24 showed a decline in acuity when tested at P35 and P42. Their acuity was only slightly better than rd10-non-treated mice. Electrophysiologic function was assessed using scotopic and photopic electroretinography (ERG) to assess rod and cone function, respectively. Photopic a- and b-wave amplitudes were significantly greater in rd10 mice treated with (+)-PTZ beginning at P14 compared with non-treated mice and those in the later-onset (+)-PTZ injection groups. Retinal architecture was visualized in living mice using spectral domain-optical coherence tomography (SD-OCT) allowing measurement of the total retinal thickness, the inner retina and the outer retina (the area most affected in rd10 mice). The outer retina measured ~35 μm in rd10 mice treated with (+)-PTZ beginning at P14, which was significantly greater than mice in the later-onset (+)-PTZ injection groups (~25 μm) and non-treated rd10 mice (~25 μm). Following the visual function studies performed in the living mice, eyes were harvested at P42 for histologic analysis. While the inner retina was largely intact in all (+)-PTZ-injection groups, there was a marked reduction in the outer retina of non-treated rd10 mice (e.g. in the outer nuclear layer there were ~10 PRCs/100 μm retinal length). The rd10 mice treated with (+)-PTZ beginning at P14 had ~20 PRCs/100 μm retinal length, whereas the mice in groups beginning P18, P21 and P24 had ~16 PRCs/100 μm retinal length. In conclusion, the data indicate that delaying (+)-PTZ injection past the onset of PRC death in rd10 mice - even by a few days - can negatively impact the long-term preservation of retinal function. Our findings suggest that optimizing the administration of Sig1R ligands is critical for retinal neuroprotection.
Identifiants
pubmed: 33310057
pii: S0014-4835(20)30655-2
doi: 10.1016/j.exer.2020.108397
pmc: PMC7808329
mid: NIHMS1657010
pii:
doi:
Substances chimiques
Receptors, sigma
0
Cyclic Nucleotide Phosphodiesterases, Type 6
EC 3.1.4.35
Pde6b protein, mouse
EC 3.1.4.35
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108397Subventions
Organisme : NEI NIH HHS
ID : P30 EY031631
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY023242
Pays : United States
Organisme : NEI NIH HHS
ID : R01 EY028103
Pays : United States
Organisme : NEI NIH HHS
ID : R21 EY028671
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Ltd.
Références
Prog Retin Eye Res. 2018 Jan;62:24-37
pubmed: 28962928
Free Radic Biol Med. 2015 Sep;86:25-36
pubmed: 25920363
Vision Res. 2002 Feb;42(4):517-25
pubmed: 11853768
Prog Retin Eye Res. 2018 Nov;67:130-149
pubmed: 30075336
J Mol Neurosci. 2020 Jun;70(6):968-980
pubmed: 32072483
Prog Retin Eye Res. 2015 Sep;48:62-81
pubmed: 26113212
Invest Ophthalmol Vis Sci. 2016 May 1;57(6):2770-81
pubmed: 27206247
Invest Ophthalmol Vis Sci. 2008 Sep;49(9):4154-61
pubmed: 18469181
Vision Res. 2007 Mar;47(5):624-33
pubmed: 17267005
Lakartidningen. 2019 Dec 2;116:
pubmed: 31794048
J Pharmacol Sci. 2015 Jan;127(1):17-29
pubmed: 25704014
Eur J Neurosci. 2013 Jun;37(11):1853-62
pubmed: 23551187
Cutan Ocul Toxicol. 2020 Mar;39(1):36-42
pubmed: 31648555
Invest Ophthalmol Vis Sci. 2017 Sep 1;58(11):4545-4558
pubmed: 28877319
Adv Exp Med Biol. 2019;1185:457-462
pubmed: 31884654
J Comp Neurol. 2007 Jan 10;500(2):222-38
pubmed: 17111372
Invest Ophthalmol Vis Sci. 2007 Oct;48(10):4785-94
pubmed: 17898305
Invest Ophthalmol Vis Sci. 2004 Dec;45(12):4611-6
pubmed: 15557474
Invest Ophthalmol Vis Sci. 2019 Jul 1;60(8):3221-3235
pubmed: 31335948
J Neurochem. 2019 Jan;148(2):307-318
pubmed: 30315650
J Neurochem. 2011 Sep;118(5):915-27
pubmed: 21689103
Sci Rep. 2015 Jun 02;5:10689
pubmed: 26033680
Cell Physiol Biochem. 2020 Feb 7;54(1):142-159
pubmed: 32028545
J Biol Chem. 2011 Mar 25;286(12):10551-67
pubmed: 21224384
Exp Eye Res. 2015 Mar;132:64-72
pubmed: 25616094
ACS Chem Neurosci. 2020 Aug 5;11(15):2173-2191
pubmed: 32589402
Free Radic Biol Med. 2019 Apr;134:604-616
pubmed: 30743048
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):5
pubmed: 32150247
Redox Biol. 2019 Jun;24:101199
pubmed: 31026769
Stem Cell Res Ther. 2020 Mar 4;11(1):98
pubmed: 32131893
Trends Pharmacol Sci. 2016 Apr;37(4):262-278
pubmed: 26869505
Brain Res Mol Brain Res. 2001 Nov 1;95(1-2):86-95
pubmed: 11687279
Invest Ophthalmol Vis Sci. 2006 Dec;47(12):5576-82
pubmed: 17122151
Eur J Pharmacol. 2006 Apr 24;536(1-2):200-3
pubmed: 16580663
J Ophthalmol. 2017;2017:9620876
pubmed: 28573047
Invest Ophthalmol Vis Sci. 2019 Oct 1;60(13):4397-4407
pubmed: 31639826
Proc Natl Acad Sci U S A. 2016 Jun 28;113(26):E3764-72
pubmed: 27298364
Exp Eye Res. 2013 Feb;107:21-31
pubmed: 23183135